Frontiers in Pharmacology (Jul 2019)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment

  • Clément Bailly,
  • Clément Bailly,
  • Aurelien Vidal,
  • Coralie Bonnemaire,
  • Françoise Kraeber-Bodéré,
  • Françoise Kraeber-Bodéré,
  • Michel Chérel,
  • Michel Chérel,
  • Amandine Pallardy,
  • Caroline Rousseau,
  • Emmanuel Garcion,
  • Franck Lacoeuille,
  • Franck Lacoeuille,
  • François Hindré,
  • Samuel Valable,
  • Myriam Bernaudin,
  • Caroline Bodet-Milin,
  • Caroline Bodet-Milin,
  • Mickaël Bourgeois,
  • Mickaël Bourgeois,
  • Mickaël Bourgeois

DOI
https://doi.org/10.3389/fphar.2019.00772
Journal volume & issue
Vol. 10

Abstract

Read online

Glioblastoma is the most common malignant adult brain tumor and has a very poor patient prognosis. The mean survival for highly proliferative glioblastoma is only 10 to 14 months despite an aggressive current therapeutic approach known as Stupp’s protocol, which consists of debulking surgery followed by radiotherapy and chemotherapy. Despite several clinical trials using anti-angiogenic targeted therapies, glioblastoma medical care remains without major progress in the last decade. Recent progress in nuclear medicine, has been mainly driven by advances in biotechnologies such as radioimmunotherapy, radiopeptide therapy, and radionanoparticles, and these bring a new promising arsenal for glioblastoma therapy. For therapeutic purposes, nuclear medicine practitioners classically use β− particle emitters like 131I, 90Y, 186/188Re, or 177Lu. In the glioblastoma field, these radioisotopes are coupled with nanoparticles, monoclonal antibodies, or peptides. These radiopharmaceutical compounds have resulted in a stabilization and/or improvement of the neurological status with only transient side effects. In nuclear medicine, the glioblastoma-localized and targeted internal radiotherapy proof-of-concept stage has been successfully demonstrated using β− emitting isotopes. Similarly, α particle emitters like 213Bi, 211At, or 225Ac appear to be an innovative and interesting alternative. Indeed, α particles deliver a high proportion of their energy inside or at close proximity to the targeted cells (within a few micrometers from the emission point versus several millimeters for β− particles). This physical property is based on particle–matter interaction differences and results in α particles being highly efficient in killing tumor cells with minimal irradiation of healthy tissues and permits targeting of isolated tumor cells. The first clinical trials confirmed this idea and showed good therapeutic efficacy and less side effects, thus opening a new and promising era for glioblastoma medical care using α therapy. The objective of this literature review is focused on the developing field of nuclear medicine and aims to describe the various parameters such as targets, vectors, isotopes, or injection route (systemic and local) in relation to the clinical and preclinical results in glioblastoma pathology.

Keywords